Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma-Reference-Cited by-同舟云学术

Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma

Published:2012-03 Issue:9 Volume:53 Page:1820-1823
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Wolf Jeffrey L.,Siegel David,Goldschmidt Hartmut,Hazell Katharine,Bourquelot Priscille M.,Bengoudifa Bourras R.,Matous Jeffrey,Vij Ravi,de Magalhaes-Silverman Margarida,Abonour Rafat,Anderson Kenneth C.,Lonial Sagar

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2012.661175

Reference15 articles.

1. Improved survival in multiple myeloma and the impact of novel therapies

2. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

3. Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges

4. Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90

5. Aggresome induction by proteasome inhibitor bortezomib and α-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells

Cited by 107 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectives;Experimental Hematology & Oncology;2024-04-23

2. Novel antimyeloma therapeutic option with inhibition of the HDAC1-IRF4 axis and PIM kinase;Blood Advances;2023-03-20

3. Outcomes with panobinostat in heavily pretreated multiple myeloma patients;Seminars in Oncology;2023-02

4. PDI inhibitor LTI6426 enhances panobinostat efficacy in preclinical models of multiple myeloma;Cancer Chemotherapy and Pharmacology;2022-04-05

5. Practical guidance for new multiple myeloma treatment regimens: A nursing perspective;Seminars in Oncology;2022-02